Piramal Pharma Limited · NSE:PPLPHARMA
Piramal Pharma — Q2 FY2024 Earnings Presentation
34 slides from Piramal Pharma's earnings presentation, Oct 28, 2023
Slide 1: Cover letter to BSE and NSE
27th October, 2023 BSE Limited National Stock Exchange of India Limited P.J. Towers, Dalal Street, Fort, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (East), Mumbai – 400 051 BSE scrip code: 543635 NSE symbol: PPLPHARMA Sub: Press Release and Investor Presentation – Unaudited Financi
Slide 2: Piramal Pharma Limited Announces Consolidated Results for Q2 and H1 FY2024
PRESS RELEASE Piramal Pharma Limited Announces Consolidated Results for Q2 and H1 FY2024 Mumbai, India | October 27, 2023: Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceuticals company, today announced its consolidated results for the Second Quarter (Q2) and Half Ye
Slide 3: Key Business Highlights for Q2FY24
Key Business Highlights for Q2FY24 Contract Development and Manufacturing Organization (CDMO): - Continued order inflow momentum in Q2FY24 – over 40% higher orders (development and new commercial orders) received in H1FY24 compared to H1FY23. - Good revenue growth visibility for FY24 driven by bette
Slide 4: Consolidated Profit and Loss Statement
Consolidated Profit and Loss Statement (In INR Crores) Reported Financials Quarterly Half Yearly Particulars YoY QoQ YoY Q2FY24 Q2FY23 Q1FY24 H1FY24 H1FY23 Change Change Change Revenue from Operations 1,911 1,720 11% 1,749 9% 3,660 3,202 14% Other Income 49 46 6% 38 28% 88 118 -26% Total Income 1,96
Slide 5: Consolidated Balance Sheet
Consolidated Balance Sheet (In INR Crores) As at Key Balance Sheet Items 30-Sep-23 31-Mar-23 Total Equity 7,758 6,773 Net Debt 3,823 4,781 Total 11,581 11,555 Net Fixed Assets 9,038 8,887 Tangible Assets 4,691 4,441 Intangible Assets including goodwill 4,347 4,446 Net Working Capital 2,148 2,307 Oth
Slide 6: Q2 and H1 FY2024 Earnings Conference Call
Q2 and H1 FY2024 Earnings Conference Call Piramal Pharma Limited will be hosting a conference call for investors / analysts on 30th October 2023 from 9:00 AM to 9:45 AM (IST) to discuss its Q2 and H1 FY2024 Results. The dial-in details for the call are as under: Event Location & Time Telephone Numbe
Slide 7: Piramal Pharma Limited Q2 & H1 FY2024 Results
Piramal Pharma Limited – Q2 & H1 FY2024 Results Presentation Piramal Pharma Limited Q2 & H1 FY2024 Results October 2023
Slide 8: Disclaimer
Piramal Pharma Limited – Q2 & H1 FY2024 Results Presentation Page 2 Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Piramal Pharma Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, r
Slide 9: Key Performance Highlights of Q2 and H1 FY2024
Piramal Pharma Limited – Q2 & H1 FY2024 Results Presentation Page 3 Key Performance Highlights of Q2 and H1 FY2024
Slide 10: Key Highlights of Q2 and H1 FY2024
Piramal Pharma Limited – Q2 & H1 FY2024 Results Presentation Page 4 Key Highlights of Q2 and H1 FY2024 Revenue from Operations grew by 11% YoY in Q2 FY2024 and 14% YoY in H1 FY2024 YoY Revenue Growth Business Segment Q2 FY2024 H1 FY2024 Contract Development and Manufacturing (CDMO) 14% 15% Complex
Slide 11: Financial Performance in Q2 and H1 FY2024
Piramal Pharma Limited – Q2 & H1 FY2024 Results Presentation Page 5 Financial Performance in Q2 and H1 FY2024 Q2 FY2024 H1 FY2024 Historically, H2 has outperformed H1 (In INR Crore) % of Full Year Revenue Revenue EBITDA Revenue 11% YoY Revenue 14% YoY 57 56 55 EBITDA 44% YoY EBITDA 58% YoY 43 44 45
Slide 12: Business-wise Performance
Piramal Pharma Limited – Q2 & H1 FY2024 Results Presentation Page 6 Business-wise Performance
Slide 13: Contract Development and Manufacturing Organization Business
Piramal Pharma Limited – Q2 & H1 FY2024 Results Presentation Page 7 Contract Development and Manufacturing Organization Business Performance Highlights Revenue performance in Q2 FY2024 (In INR Crore) Continued momentum in order inflows in H1 FY2024: 1,068 • New orders# in H1FY24 higher by over 40%
Slide 14: Deep Pipeline of Development Projects across Multiple Phases
Piramal Pharma Limited – Q2 & H1 FY2024 Results Presentation Deep Pipeline of Development Projects across Multiple Phases High proportion of Commercial and Phase III development revenue Increasing share of Innovation* related work FY23 Revenue by Services Contribution from Innovation related work Pr
Slide 15: Three Broad Archetypes of CDMO Companies
Piramal Pharma Limited – Q2 & H1 FY2024 Results Presentation Three Broad Archetypes of CDMO Companies Archetype Description What have players done to win End-to-end value chain coverage • Consistent investment over the years to develop capabilities across during the lifecycle of molecule (e.g., valu
Slide 16: Providing Integrated Services with Differentiated Offerings
Piramal Pharma Limited – Q2 & H1 FY2024 Results Presentation Page 10 Providing Integrated Services with Differentiated Offerings Revenue (US$ mn) from Contribution of Differentiated Differentiated Offerings Offerings to CDMO revenue Peptide Potent sterile injectables (Turbhe) (Lexington) 196 37% Hig
Slide 17: Continue to Maintain Best-in-Class Quality Track Record
Piramal Pharma Limited – Q2 & H1 FY2024 Results Presentation Page 11 Continue to Maintain Best-in-Class Quality Track Record 300+ Regulatory Inspections# since FY12 with zero OAI* ~125 audits annually by customers USFDA Inspections 44 Customer Audits Total Regulatory Inspections 35 36 29 29 197 26 2
Slide 18: Complex Hospital Generics Business
Piramal Pharma Limited – Q2 & H1 FY2024 Results Presentation Page 12 Complex Hospital Generics Business Performance Highlights Revenue growth in Q2 FY2024 (In INR Crore) Steady revenue growth of 13% YoY in H1 FY2024 primarily on account of healthy 589 volume led growth in Inhalation Anesthesia (IA
Slide 19: Key Priorities
Piramal Pharma Limited – Q2 & H1 FY2024 Results Presentation Page 13 Key Priorities Expand capacities to meeting growing demand of IA products Leverage worldwide marketing and sales network Inhalation anesthesia facility (Digwal, India) Setting up manufacturing lines for Sevoflurane in our Digwal fa
Slide 20: India Consumer Healthcare Business
Piramal Pharma Limited – Q2 & H1 FY2024 Results Presentation Page 14 India Consumer Healthcare Business Performance Highlights Revenue growth in Q2 FY2024 New Product launches - 7 new products and 2 new SKUs launched in Q2 FY2024. New (In INR Crore) products launched in last 24 months contribute t
Slide 21: Focus on Power Brands with Continuous Investments in Brand Promotion and Marketing
Piramal Pharma Limited – Q2 & H1 FY2024 Results Presentation Page 15 Focus on Power Brands with Continuous Investments in Brand Promotion and Marketing Investments in brand promotion and marketing Strong growth in our power brands (In INR Crore) % of ICH sales (In INR Crore) 38% CAGR 16% 15% 15% 14%
Slide 22: Leverage Multi-channel Distribution Network and New Product Launches
Piramal Pharma Limited – Q2 & H1 FY2024 Results Presentation Page 16 Leverage Multi-channel Distribution Network and New Product Launches Presence across traditional and alternate trade channels Regular new product launches contributing to growth Presence in ~180K chemists and cosmetics stores and 1
Slide 23: Abbvie Therapeutics India Private Limited
Piramal Pharma Limited – Q2 & H1 FY2024 Results Presentation Page 17 Abbvie Therapeutics India Private Limited* Joint Venture Arrangement Ownership Ownership 49% 51% In FY2023, the JV reported# revenue of Rs.446Cr with PAT margin of 25% Continue to be one of the market leaders in 400+ Strong presenc
Slide 24: Sustainability Initiatives
Piramal Pharma Limited – Q2 & H1 FY2024 Results Presentation Page 18 Sustainability Initiatives
Slide 25: Piramal Pharma Sustainability Report FY2022-23
Piramal Pharma Limited – Q2 & H1 FY2024 Results Presentation Page 19 Piramal Pharma Sustainability Report FY2022-23 Sustainability Report FY2022-23 Piramal Pharma released its Sustainability Report FY2023, articulating its ESG journey to accelerate the pace of integrating sustainable practices ESG T
Slide 26: Key ESG Highlights in FY2023
Piramal Pharma Limited – Q2 & H1 FY2024 Results Presentation Page 20 Key ESG Highlights in FY2023 “Climate change is one of the world’s most pressing concerns, and its debilitating effects are evident in every aspect of life. We, at Piramal Pharma, are committed to conserving resources as we recogni
Slide 27: Key ESG Highlights in FY2023
Piramal Pharma Limited – Q2 & H1 FY2024 Results Presentation Page 21 Key ESG Highlights in FY2023 “Overall, sustainability for us is more than just being compliant with regulatory norms and standards. It is about giving back to the environment and community through purpose-driven operations and resp
Slide 28: Key Strategic Priorities
Piramal Pharma Limited – Q2 & H1 FY2024 Results Presentation Page 22 Key Strategic Priorities
Slide 29: Key Strategic Priorities
Piramal Pharma Limited – Q2 and H1 FY2024 Results Presentation Page 23 Key Strategic Priorities 1 Drive demand in CDMO business by increasing the proposal velocity and win rate 2 Delivering consistent revenue growth and improving profitability Track record of 3 Pursuing organic and inorganic growth
Slide 30: Financials
Piramal Pharma Limited – Q2 & H1 FY2024 Results Presentation Page 24 Financials
Slide 31: Consolidated Financials Highlights
Piramal Pharma Limited – Q2 & H1 FY2024 Results Presentation Page 25 Consolidated Financials Highlights (In INR Crores or as stated) Particulars Q2 FY2024 Q2 FY2023 YoY Change Q1 FY2024 QoQ Change Revenue from Operations* 1,911 1,720 11% 1,749 9% CDMO 1,068 940 14% 898 19% CHG 589 562 5% 617 -5% ICH
Slide 32: Consolidated Financials Highlights – Balance Sheet
Piramal Pharma Limited – Q2 & H1 FY2024 Results Presentation Page 26 Consolidated Financials Highlights – Balance Sheet (In INR Crores) Key Balance Sheet Items As on 30-Sep-23 As on 31-Mar-23 Total Equity 7,758 6,773 Net Debt 3,823 4,781 Total 11,581 11,555 Net Fixed Assets 9,038 8,887 Tangible Asse
Slide 33: Dial-in details for Q2 FY2024 Earnings Conference Call
Piramal Pharma Limited – Q2 & H1 FY2024 Results Presentation Page 27 Dial-in details for Q2 FY2024 Earnings Conference Call Event Location & Time Telephone Number +91 22 6280 1461 / +91 22 7115 8320 (Primary Number) India – 09:00 AM IST 1 800 120 1221 (Toll free number) USA – 11:30 PM Toll free numb
Slide 34: For Investor Queries
Piramal Pharma Limited – Q2 & H1 FY2024 Results Presentation Page 28 For Investor Queries: Gagan Borana General Manager – Investor Relations & Sustainability Email : gagan.borana@piramal.com Phone : +91 22 3802 3090